(RedirectedfromMemorialSloan–KetteringCancerCenter) Jumptonavigation Jumptosearch HospitalinUS,UnitedStatesMemorialSl..">
|Memorial Sloan Kettering Cancer Center|
|Location||Manhattan, New York City, US, United States|
|Affiliated university||Weill Cornell Graduate School of Medical Sciences|
|Emergency department||Urgent care center|
|Founded||1884 (as New York Cancer Hospital)|
|Lists||Hospitals in the United States|
|Other links||Hospitals in New York|
Memorial Sloan Kettering Cancer Center (MSK or MSKCC) is a cancer treatment and research institution in New York City, founded in 1884 as the New York Cancer Hospital. MSKCC is the largest and oldest private cancer center in the world, and is one of 47 National Cancer Institute-designated Comprehensive Cancer Centers. Its main campus is located at 1275 York Avenue, between 67th and 68th Streets, in Manhattan.
Memorial Hospital was founded on the Upper West Side of Manhattan in 1884 as the New York Cancer Hospital by a group that included John Jacob Astor III and his wife Charlotte. The hospital appointed William B. Coley as an attending surgeon, who pioneered an early form of immunotherapy to eradicate tumors. Rose Hawthorne, daughter of author Nathaniel Hawthorne, trained there in the summer of 1896 before founding her own order, Dominican Sisters of Hawthorne. In 1899, the hospital was renamed General Memorial Hospital for the Treatment of Cancer and Allied Diseases.
Around 1910 James Ewing, a professor at Cornell University's medical college, established a collaboration with Memorial Hospital with the help and funding of industrialist and philanthropist James Douglas, who gave $100,000 to endow twenty beds for clinical research, equipment for working with radium, and a clinical laboratory for that purpose. Douglas' enthusiasm and funding for development of radiation therapy for cancer inspired Ewing to become one of the pioneers in developing this treatment. Ewing soon took over effective leadership of clinical and laboratory research at Memorial. In 1916 the hospital was renamed again, dropping "General" to become known simply as Memorial Hospital. The first fellowship training program in the US was created at Memorial in 1927, funded by the Rockefellers. In 1931 the then-most-powerful 900k-volt X-ray tube was put into use in radiation-based cancer treatment at Memorial; the tube had been built by General Electric over several years. In 1931 Ewing was formally appointed president of the hospital, a role he had effectively played until then, and was featured on the cover of Time Magazine as "Cancer Man Ewing"; the accompanying article described his role as one of the most important cancer doctors of his era. He worked at the Memorial until his retirement, in 1939. Under his leadership, Memorial became a model for other cancer centers in the United States, combining patient care with clinical and laboratory research, and it was said of him that "the relationship of Ewing to the Memorial Hospital can best be expressed in the words of Emerson, 'Every institution is but the lengthening shadow of some man.' Dr. Ewing is the Memorial Hospital".
In 1934, John D. Rockefeller, Jr. donated land on York Avenue for a new location. Two years later, he granted Memorial Hospital $3,000,000 and the hospital began their move across town. Memorial Hospital officially reopened at the new location in 1939. In 1945, the chairman of General Motors, Alfred P. Sloan, donated $4,000,000 to create the Sloan-Kettering Institute for Cancer Research through his Sloan Foundation, and Charles F. Kettering, GM's vice president and director of research, personally agreed to oversee the organization of a cancer research program based on industrial techniques. The originally independent research institute was built adjacent to Memorial Hospital.
In 1948 Cornelius P. Rhoads became the director of Memorial. Rhoads had run chemical weapons programs for the US army in World War II, and had been involved in the work that led to the discovery that nitrogen mustards could potentially be used as cancer drugs.:91–92 He fostered a collaboration between Joseph H. Burchenal, a clinician at Memorial and Gertrude B. Elion and George H. Hitchings at Burroughs Wellcome, who had discovered 6 MP; the collaboration led to the development and eventual wide use of this cancer drug.:91–92
From the mid-1950s to the mid-1960s Chester M. Southam conducted pioneering clinical research on virotherapy and cancer immunotherapy at MSK; however he conducted his research on people without their informed consent. He did this to patients under his care or others' care, and to prisoners. In 1963 some doctors objected to the lack of consent in his experiments and reported him to the Regents of the University of the State of New York which found him guilty of fraud, deceit, and unprofessional conduct, and in the end he was placed on probation for a year. Southam's research experiments and the case at the Regents were followed in the New York Times.
In 1960, Memorial Sloan Kettering Cancer Center was formed as a new corporation to coordinate the two institutions; John Heller, the former director of the National Cancer Institute was named its president. At the end of the 1960s, as the field of pediatric oncology began seeing success in treating children with cancer, Memorial opened an outpatient pediatric day hospital, partly to deal with the growing number of cancer survivors. In the early 1970s, Burchenal and Benno Schmidt, a professional investor and trustee of MSK, were appointed to the presidential panel that initiated the U.S. federal government's War on Cancer in the early 1970s.:184 When Congress passed the National Cancer Act of 1971 as part of that effort, Memorial Sloan Kettering was designated as one of only three Comprehensive Cancer Centers nationwide. In 1977, Jimmie C. Holland established a full-time psychiatric service at MSK dedicated to helping people with cancer cope with their disease and its treatment; it was one of the first such programs and was part of the creation of the field of psycho-oncology.
In 1980 Memorial Hospital and the Sloan-Kettering Institute formally merged into a singular entity under the Memorial Sloan Kettering Cancer Center name.
In 2000, former NIH director Harold Varmus became the director of MSK. During his tenure, he helped build new facilities, strengthened the bond between MSK's clinical and research arms, and fostered collaborations with other institutions, including Weill-Cornell Medical College and Rockefeller University.
In 2006, MSK opened the Mortimer B. Zuckerman Research Center, a 23-story building which houses more than 100 laboratories.
Craig B. Thompson, oncologist and researcher, was appointed MSK's president and CEO in 2010. The following year, MSK was rated the third most successful nonprofit in terms of FDA-approved drugs and vaccines, behind the National Institutes of Health and the University of California system. In 2012, Thompson appointed José Baselga as physician-in-chief, who directs the clinical side of MSK. That same year, a collaboration with IBM's Watson was announced with the goal of developing new tools and resources to better tailor diagnostic and treatment recommendations for patients. The director of SKI, the research arm of MSK, Joan Massagué was appointed in 2013.
MSK currently employs over 1,000 physicians and treats more than 600,000 patients with approximately 400 types of cancer annually.
The Memorial Sloan Kettering Bendheim Integrative Medicine Center occupies 1429 First Avenue on the corner of East 74th Street in Manhattan. The former bank was built in the 1930s by Perkins and Will as architects. It was remodeled for use by Memorial Sloan Kettering in 1997.
MSK has an extensive history of notable discoveries in cancer research. The research arm of MSK is still known as the Sloan Kettering Institute after the merger with Memorial Hospital. Memorial Hospital separately houses a number of laboratories. In 2011, a study ranked MSK third among public sector research institutes after the NIH and University of California system.
Notable cancer treatments developed at MSK include chimeric antigen receptor therapy, enzalutamide, HSP-90 inhibitors, Ipilimumab, Pralatrexate, Filgrastim, Thyrogen, aldesleukin, Zolinza, Ganite, Trisenox, clofarabine,
Research is organized into several programs within the Sloan Kettering Institute and Memorial Hospital:
A number of Collaborative Research Centers have also been established at MSK.
In 2004, the Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences was opened at Memorial Sloan Kettering Cancer Center, with the goal of furthering research by introducing students to an interactive and innovative environment. The first students graduated in 2012.
The Tri-Institutional MD–PhD Program is a partnership of MSKCC, The Rockefeller University, and Weill Cornell Graduate School of Medical Sciences, and Cornell University. The biomedical program takes advantage of the close proximity of these three institutions for collaboration on biomedical research and Cornell's MD–PhD program. The Tri-Institutional Training Program in Computational Biology and Medicine is a similar partnership.
In 2015 Charity Watch rated Memorial Sloan Kettering Cancer Center an "A". Heads of the charity received $2,107,939 to $2,639,669 salary/compensation from the charity. CEO Craig B. Thompson received $2,554,085 salary/compensation from the charity.